211 related articles for article (PubMed ID: 36309558)
1. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
Senapati J; Jabbour E; Kantarjian H; Short NJ
Leukemia; 2023 Jan; 37(1):5-17. PubMed ID: 36309558
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
3. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
Short NJ; Senapati J; Jabbour E
Curr Hematol Malig Rep; 2023 Dec; 18(6):234-242. PubMed ID: 37651057
[TBL] [Abstract][Full Text] [Related]
4. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
[TBL] [Abstract][Full Text] [Related]
5. [Management of advanced-phase chronic myeloid leukemia].
Kitanaka A
Rinsho Ketsueki; 2016; 57(10):1962-1971. PubMed ID: 27725594
[TBL] [Abstract][Full Text] [Related]
6. Blast and accelerated phase CML: room for improvement.
How J; Venkataraman V; Hobbs GS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):122-128. PubMed ID: 34889372
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
[TBL] [Abstract][Full Text] [Related]
8. B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.
Yohannan B; George B
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233138
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
[TBL] [Abstract][Full Text] [Related]
10. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Copland M
Br J Haematol; 2022 Dec; 199(5):665-678. PubMed ID: 35866251
[TBL] [Abstract][Full Text] [Related]
11. Transplantation in CML in the TKI era: who, when, and how?
Niederwieser C; Kröger N
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):114-122. PubMed ID: 36485123
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
13. Diagnosing and managing advanced chronic myeloid leukemia.
Deininger MW
Am Soc Clin Oncol Educ Book; 2015; ():e381-8. PubMed ID: 25993200
[TBL] [Abstract][Full Text] [Related]
14. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia: overview of new agents and comparative analysis.
Jain P; Kantarjian H; Cortes J
Curr Treat Options Oncol; 2013 Jun; 14(2):127-43. PubMed ID: 23572291
[TBL] [Abstract][Full Text] [Related]
16. Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Saxena K; Jabbour E; Issa G; Sasaki K; Ravandi F; Maiti A; Daver N; Kadia T; DiNardo CD; Konopleva M; Cortes JE; Yilmaz M; Chien K; Pierce S; Kantarjian H; Short NJ
J Hematol Oncol; 2021 Jun; 14(1):94. PubMed ID: 34130720
[TBL] [Abstract][Full Text] [Related]
17. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pandor A; Stevenson M; Stevens J; James MM; Hamilton J; Byrne J; Rudin C; Rawdin A; Wong R
Pharmacoeconomics; 2018 Aug; 36(8):903-915. PubMed ID: 29480454
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Verma D; Kantarjian HM; Jones D; Luthra R; Borthakur G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Sep; 114(11):2232-5. PubMed ID: 19531657
[TBL] [Abstract][Full Text] [Related]
20. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
